Discover 1,567 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,567
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
for
B-cell Non-Hodgkin Lymphoma (B-NHL)
Location: New Brunswick NJ, Boston MA, Chicago IL, Austin TX
Sponsor: Cellectis S.A.
Sex: All
Age: 18 - 70+
Code: NCT05607420
Phase1, Phase2, Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
for
Thymoma, Thymic Carcinoma
Location: Hackensack NJ, Washington D.C. DC, Chicago IL,
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT06248515
Phase2, Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
for
Small Cell Lung Cancer
Location: Hackensack NJ, Boston MA, Buffalo NY, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06780137
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
for
Solid Tumors
Location: Hackensack NJ, New Haven CT, Los Angeles CA
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT05471856
Phase1, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: New Brunswick NJ, New Haven CT, Philadelphia PA,